Skip to content

The Efficacy of mindfulness-based cognitive therapy on reduction of psychological symptoms,craving beliefs and increase self-efficacy in opioid abusers

Mindfulness-based cognitive therapy on reduction of psychological symptoms,craving beliefs and increase self-efficacy in opioid abusers

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2017081325160N7
Enrollment
40
Registered
2017-09-25
Start date
2017-04-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

opioid abusers. This block contains a wide variety of disorders that differ in severity and clinical form but that are all attributable to the use of one or more psychoactive substances, which may or may not have been medically prescribed. The third character of the code

Interventions

Intervention 1: experimental group: The present study is a pilot design with two experimental group (mindfulness-based cognitive therapy) and the control group. in this study, the pilot project is pre
Behavior
experimental group: The present study is a pilot design with two experimental group (mindfulness-based cognitive therapy) and the control group. in this study, the pilot project is pretest – posttest
in this study, control group does not receive no intervention.

Sponsors

vice chancellor for research, Shiraz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
20 Years to 45 Years

Inclusion criteria

Inclusion criteria: Inclusion major eligibility criteria to study: Being male and having age between 20 to 45 years ; having a minimum secondary education ; substance abuse and independency to Stimulants ; having diagnostic criteria for the use of opioids to the initial diagnosis of a psychiatrist and the diagnosis of clinical psychologist based on the results of a structured clinical interview for axial disturbances (DSM-5) ; dependence on at least one opiate substance (opium, heroin, tramadol and Similar substances) based on clinical interviews ; passed at least one year of drug ; lack of participation in psychotherapy groups including NA in the last 6 months ; complete consent for participation in research. Exclusion major eligibility criteria of study: Having mental retardation ; psychotic disorders ; organic brain disorder ; having serious thoughts on suicide based on psychiatrist interviews ;having complete criteria for personality disorder in axis II based on the results of structured interviews of the disordered axis two ; employment in psychology or counseling ; receiving another psychological intervention at the same time or having a kinship or friendship with each member of the intervention group ; decisided to leave the group.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Psychological symptoms. Timepoint: weekly to 2 months. Method of measurement: Clinical Interview for Focal I Disorders in DSM-IV-Clinical Version (SCID-I / CV).

Secondary

MeasureTime frame
Craving beliefs. Timepoint: weekly to 2 months. Method of measurement: Addiction Severity Index (ASI) - Brief Symptom Inventory (BSI).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactJamshid Ahmadi M.D.

Shiraz University of Medical Sciences

jamshid_ahmadi@yahoo.com+98 71 3646 1511

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026